1. AHRO : Austin Health Research Online

Thomas John

View Statistics Email Alert RSS Feed
 Claim profile

Profile

Loading... 2 0 20 0 false
Credit Name
Thomas John
Full Name
John, Thomas
 
Variants
John, Tom
 
Department
 
Personal Site
https://www.onjcancercentre.org/profile/a-prof.-tom-john
 
ORCID
Loading... 3 0 20 0 false

Publications

Refined By:
Author:  Chia, Puey Ling

Results 1-14 of 14 (Search time: 0.008 seconds).

Publication YearTitleAuthor(s)
1Mar-2021Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival.Chia, Puey Ling ; Parakh, Sagun ; Russell, Prudence; Gan, Hui K ; Asadi, Khashayar ; Gebski, Val; Murone, Carmel ; Walkiewicz, Marzena; Liu, Zhanqi; Thapa, Bibhusal ; Scott, Fiona E; Scott, Andrew M ; John, Thomas 
2Dec-2020Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort.Chia, Puey Ling ; Russell, Prudence; Asadi, Khashi; Thapa, Bibhusal ; Gebski, Val; Murone, Carmel ; Walkiewicz, Marzena; Eriksson, Ulf; Scott, Andrew M ; John, Thomas 
32-Oct-2020Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma.Chia, Puey Ling ; Parakh, Sagun ; Tsao, Ming-Sound; Pham, Nhu-An; Gan, Hui K ; Cao, Diana; Burvenich, Ingrid J G; Rigopoulos, Angela; Reilly, Edward B; John, Thomas ; Scott, Andrew M 
4Oct-2020Targeting Multiple EGFR Expressing Tumors with a Highly Potent Tumor-Selective Antibody Drug Conjugate.Anderson, Mark G; Falls, Hugh D; Mitten, Michael J; Oleksijew, Anatol; Vaidya, Kedar S; Boghaert, Erwin R; Gao, Wenqing; Palma, Joann P; Cao, Diana; Chia, Puey Ling ; John, Thomas ; Gan, Hui K ; Scott, Andrew M ; Reilly, Edward B
527-Mar-2019Epidermal growth factor receptor (EGFR)-targeted therapies in Mesothelioma.Chia, Puey Ling ; Scott, Andrew M ; John, Thomas 
61-Apr-2018Personalized Chemosensitivity Assays for Mesothelioma: Are They Worth the Effort?John, Thomas ; Chia, Puey Ling 
719-Jan-2018Personalized chemosensitivity assays for mesothelioma- is it worth the effort?John, Thomas ; Chia, Puey Ling 
8Aug-2017Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian contextItchins, M; Chia, Puey Ling ; Hayes, SA; Howell, VM; Gill, AJ; Cooper, WA; John, Thomas ; Mitchell, Paul L R ; Millward, M; Clarke, SJ; Solomon, B; Pavlakis, N
912-Oct-2016Targeting the vasculature: anti-angiogenic agents for malignant mesotheliomaChia, Puey Ling ; Russell, Prudence A; Scott, Andrew M ; John, Thomas 
10Aug-2016Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatmentChia, Puey Ling ; Do, Hongdo; Morey, Adrienne; Mitchell, Paul L R ; Dobrovic, Alexander ; John, Thomas 
11Jun-2016Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC).Chia, Puey Ling ; John, Thomas 
1231-May-2016Current and evolving methods to visualize biological data in cancer researchChia, Puey Ling ; Gedye, Craig; Boutros, Paul C; Wheatley-Price, Paul; John, Thomas 
13Dec-2015Vortex Keratopathy Presumed Secondary to AZD9291.Chia, Puey Ling ; John, Thomas 
1420-Nov-2014Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors.Chia, Puey Ling ; Mitchell, Paul L R ; Dobrovic, Alexander ; John, Thomas